CVBio Is a Clinical-Stage Biotechnology Company Advancing Virus-Driven Immunotherapies for Cancer
CVBio is a clinical-stage biotechnology company advancing next-generation, virus-driven immunotherapies for cancer, with a core focus on adult and pediatric glioblastomas. Headquartered in Houston, Texas, it was formed to carry forward and build upon a unique set of clinical-stage therapeutic assets acquired from DNAtrix.
Clinical Experience and Proven Outcomes
Our lead programs leverage a robust foundation of clinical experience—more than 200 patients treated across multiple trials—with a strong track record of safety and efficacy. Data from these studies show our therapies are well tolerated, with meaningful tumor size reductions, increased mean survival rates, and, in some cases, durable and ongoing responses.
Global Collaborations
CVBio partners with world-class institutions and principal investigators, including Clinica Universidad de Navarra (Pamplona, Spain) and the Princess Máxima Center for Pediatric Oncology (Utrecht, Netherlands), who bring deep expertise and a shared commitment to advancing care in aggressive brain tumors. Many of these institutions have already pledged substantial resources and financial support for our upcoming trials.
Next-Generation Trial Design
Our programs are supported by the Pediatric Neuro-Oncology Consortium (PNOC) and are entering a new phase of development, driven by optimized trial designs aimed at generating actionable insights. These studies will incorporate higher dosing and repeat administration strategies, in contrast to the single-dose regimens used previously—approaches that aim to significantly enhance therapeutic impact.
CVBio continues to expand its pipeline by developing viruses armed with potent immunomodulators aimed at unleashing strong, targeted immune attacks on cancer.
News and Resources
